drugset / Trial / NCT00002574

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

NCT00002574

Phase 2 Completed 87 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells.

Timeline

Start
1994-09
Primary completion
2001-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Homoharringtonine Small molecule
Subject interferon alfa-2b Protein / enzyme biologic

Indications